ArticleProceedings of the National Academy of Sciences of the United States of America2006
An antibody produced in tobacco expressing a hybrid beta-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 144 citations in OpenAlex.
- N-Glycoengineering of insect cells for tri-antennary N-glycan biosynthesis.Scientific reports · 2026Article
- Advances in research on pharmacological mechanisms of anatabine: from nicotinic modulation to multitarget therapeutic potential.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Advances and challenges in plant N-glycoengineering: when fucosylation matters.Frontiers in plant science · 2025Review
- Trafficking and localization of Golgi-residentFrontiers in plant science · 2025Review
- Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Production andFrontiers in plant science · 2023Article
- Unexpected Arabinosylation after Humanization of Plant ProteinFrontiers in bioengineering and biotechnology · 2022Article
- Engineering of Plants for Efficient Production of Therapeutics.Molecular biotechnology · 2021Review
- Glyco-Engineering of Plant-Based Expression Systems.Advances in biochemical engineering/biotechnology · 2021Article
- Glycoengineering tobacco plants to stably express recombinant human erythropoietin with different N-glycan profiles.International journal of biological macromolecules · 2020Article
- Stable Protein Sialylation in Physcomitrella.Frontiers in plant science · 2020Article
- Lack of the α1,3-Fucosyltransferase Gene (International journal of molecular sciences · 2018Article
- N-Glycosylation of an IgG antibody secreted by Nicotiana tabacum BY-2 cells can be modulated through co-expression of human β-1,4-galactosyltransferase.Transgenic research · 2017Article
- Potential of plants to produce recombinant protein products.Journal of plant biology = Singmul Hakhoe chi · 2016Review
- Characterization of plants expressing the human β1,4-galactosyltrasferase gene.Plant physiology and biochemistry : PPB · 2015Article
- C-Terminally fused affinity Strep-tag II is removed by proteolysis from recombinant human erythropoietin expressed in transgenic tobacco plants.Plant cell reports · 2015Article
- The transmembrane domain of N -acetylglucosaminyltransferase I is the key determinant for its Golgi subcompartmentation.The Plant journal : for cell and molecular biology · 2014Article
- Expression of natural human β1,4-GalT1 variants and of non-mammalian homologues in plants leads to differences in galactosylation of N-glycans.Transgenic research · 2014Article
- Protein N-glycosylation in eukaryotic microalgae and its impact on the production of nuclear expressed biopharmaceuticals.Frontiers in plant science · 2014Review
- Plant glyco-biotechnology on the way to synthetic biology.Frontiers in plant science · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-glycosylation of a mAb may have a major impact on its therapeutic merits. Here, we demonstrate that expression of a hybrid enzyme (called xylGalT), consisting of the N-terminal domain of Arabidopsis thaliana xylosyltransferase and the catalytic domain of human beta-1,4-galactosyltransferase I (GalT), in tobacco causes a sharp reduction of N-glycans with potentially immunogenic core-bound xylose (Xyl) and fucose (Fuc) residues as shown by Western blot and MALDI-TOF MS analysis. A radioallergosorbent test inhibition assay with proteins purified from leaves of WT and these transgenic tobacco plants using sera from allergic patients suggests a significant reduction of potential immunogenicity of xylGalT proteins. A mAb purified from leaves of plants expressing xylGalT displayed an N-glycan profile that featured high levels of galactose, undetectable xylose, and a trace of fucose. Hence, a transgenic plant expressing the hybrid GalT might yield more effective and safer monoclonals for therapeutic purposes than WT plants and even transgenic plants expressing the unchanged GalT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.